Clinical Trials Logo

Glabellar Frown Lines clinical trials

View clinical trials related to Glabellar Frown Lines.

Filter by:

NCT ID: NCT06124794 Not yet recruiting - Clinical trials for Glabellar Frown Lines

The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines

Start date: December 11, 2023
Phase: Phase 3
Study type: Interventional

This clinical trial is an extended clinical trial for test subjects who participated in the phase 3 clinical trial of PT_BTA_P3_21 (clinical trial plan number) and completed follow-up observation up to 16 weeks after administration of clinical trial drugs, and evaluates the effectiveness and safety of repeated administration of protoxin in those with moderate or severe brow wrinkles.

NCT ID: NCT05894109 Not yet recruiting - Clinical trials for Glabellar Frown Lines

Efficacy of Zinc Supplementation on Botox Treated Forehead Rhytids

Start date: March 2024
Phase: N/A
Study type: Interventional

The current literature suggests that zinc supplementation may increase the duration of botulinum toxin; however, each study had their limitations. Further, no one has studied the effect of zinc supplementation for botulinum toxin treatment of the forehead. The purpose of this study is to evaluate the effect of zinc supplementation on frontalis muscle denervation by objectively assessing the degree of forehead rhytids and movement of the eyebrows.

NCT ID: NCT05766683 Active, not recruiting - Clinical trials for Glabellar Frown Lines

Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines

Start date: March 14, 2023
Phase: Phase 1
Study type: Interventional

STUDY QUESTION: Does the depth of injection of onabotulinumtoxinA neurotoxin in the glabellar complex affect efficacy of the BoTN for the improvement of glabellar frown lines? STUDY AIM - Primary objective: Compare the efficacy of onabotulinumtoxinA neurotoxin injected at the depth of 2mm vs 4mm for the improvement of glabellar lines - Secondary objective: Determine any adverse effects of onabotulinumtoxinA neurotoxin injected at the depth of 2mm vs 4mm RATIONALE FOR THE PROJECT: Although the use of BoTN for treatment of glabellar lines has long been established as safe and effective, the optimal depth of injection has not been established. Our project hopes to establish the optimal depth of injection for onabotulinumtoxinA neurotoxin for maximal improvement of glabellar lines with minimal adverse effects

NCT ID: NCT05623410 Active, not recruiting - Clinical trials for Glabellar Frown Lines

Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines

Start date: October 11, 2022
Phase: Phase 3
Study type: Interventional

Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison with Xeomin for a total of 16 weeks after the administration in treatment of glabellar frown lines.

NCT ID: NCT05565950 Active, not recruiting - Clinical trials for Glabellar Frown Lines

AI-09 In Subjects With Glabellar Lines, GL-101

Start date: October 3, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

AI-09 In Subjects with Glabellar Lines

NCT ID: NCT05517538 Completed - Wrinkle Clinical Trials

Split-face Study: Cosmetic Botulinum Toxin Type A Injection Under Electromyography-guidance Versus Conventional Palpation Technique

Start date: August 9, 2021
Phase: N/A
Study type: Interventional

The aim of this study was to compare between the conventional palpation method of botulinum toxin type A injection and the electromyography-guided method using clinical parameters and electromyography analysis.

NCT ID: NCT05481931 Recruiting - Clinical trials for Glabellar Frown Lines

Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines

Start date: March 15, 2023
Phase:
Study type: Observational

Non-interventional PASS of NUCEIVA for the treatment of moderate-to-severe glabellar lines to provide additional characterisation of the long-term safety of NUCEIVA in the real-world clinical practice setting.

NCT ID: NCT05364580 Completed - Clinical trials for Glabellar Frown Lines

The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines

Start date: March 6, 2023
Phase: Phase 3
Study type: Interventional

This study will be conducted in Phase Ⅲ clinical trials. In Phase Ⅲ, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at a total of 20U(4U/0.1mL each) in five sites of the glabellar lines. The investigational product is administered once, maintaining double-blind for a total of 16 weeks of observation. Thereafter, efficacy and safety are assessed by comparing with BOTOX® after regular visits conducted at 4,8,12 and 16 weeks.

NCT ID: NCT05321979 Completed - Clinical trials for Glabellar Frown Lines

Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

Start date: February 7, 2022
Phase: Phase 3
Study type: Interventional

This study is intended to evaluate long-term safety and efficacy of MBA-P01 in treatment of glabellar lines.

NCT ID: NCT05320393 Completed - Clinical trials for Glabellar Frown Lines

Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

Start date: March 30, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to demonstrate the safety and duration of effect of 40 Units of prabotulinumtoxinA-xvfs (Jeuveau®) in providing temporary improvement in the appearance of moderate to severe glabellar lines (frown lines, which are the vertical lines that develop between the eyebrows) in adult participants. It will also determine if the duration of effect of 40 Units of Jeuveau® is greater than that of 20 Units of Jeuveau® and 20 Units of Botox® Cosmetic.